Cancer Letters
Volume 243, Issue 2 , Pages 246-254 , 18 November 2006

Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1

  • Yuan-Gen Fu

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • ,
  • Joseph J.Y. Sung

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • ,
  • Kai-Chun Wu

      Affiliations

    • Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China
    • ,
  • Alfa H.C. Bai

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • ,
  • Martin C.W. Chan

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • ,
  • Jun Yu

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • ,
  • Dai-Ming Fan

      Affiliations

    • Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China
    • ,
  • Wai K. Leung

      Affiliations

    • Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    • Corresponding Author InformationCorresponding author. Tel.: +852 2632 3140; fax: +852 2637 3852.

Received 23 August 2005 ,Revised 22 September 2005 ,Accepted 27 November 2005.

References 

  1. Papetti M, Herman IM. Mechanism of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 2002;282:947–970
  2. Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsummura M, et al. Potential role of the angiopoietin/Tie2 system in ischemia-induced retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2003;44:393–402
  3. Rosen ED, Spiegelman BM. PPARγ, a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001;276:37731–37734
  4. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 1997;8:159–166
  5. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–86
  6. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA. 1998;95:7614–7619
  7. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–252
  8. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer in vitro and in vivo. Cancer Res. 1998;58:3344–3352
  9. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, et al. Activation of the peroxisome proliferator-activated receptor-gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 1998;4:1053–1057
  10. Spiegelman BM. PPARgamma in monocytes: less pain, any gain?. Cell. 1998;93:153–155
  11. Leung WK, Bai AH, Chan VY, Yu J, To KF, Wu JR, et al. Effect of peroxisome proliferators-activated receptor-gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut. 2004;53:331–338
  12. Gralinski MR, Rowse PE, Breider MA. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J. Cardiovasc. Pharmacol. 1998;31:909–913
  13. Xin X, Yang S, Kowalski J, Gervitsen ME. Peroxisome proliferator-activated receptorγ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 1999;13:9116–9121
  14. Fu YG, Sung JJY, Wu KC, Wu HP, Yu J, Chan VYW, et al. Inhibition of gastric cancer associated angiogenesis by COX-2 inhibitor or antisense COX-2 transfectant. Cancer Lett. 2005;224:243–252
  15. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, et al. PPARγ is required for placental, cardiac and adipose tissue development. Mol. Cell. 1999;4:585–595
  16. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 2002;110:923–932
  17. Bourcier MN, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 1999;19:546–551
  18. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, et al. Peroxisome proliferator-activated receptorγ ligands inhibit choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2000;41:2309–2317
  19. Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H, et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2000;271:571–574
  20. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferators-activated receptors in bladder cancer cells. J. Biol. Chem. 2002;277:23534–23543
  21. Inoue M, Itoh H, Tanaka T, Chun TH, Doi K, Fukunaga Y, et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arterioscler. Thromb. Vasc. Biol. 2001;21:560–566
  22. Grant DS, Lelkes PI, Fukuda K, Kleinman HK. Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro. In Vitro Cell. Dev. Biol. 1991;27A:327–336
  23. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  24. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Ang-1 induces sprouting angiogenesis in vitro. Curr. Biol. 1998;8:529–532
  25. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Ang-1 is an a apoptosis survival factor for endothelial cells. Fed. Eur. Biochem. Soc. Lett. 1999;448:249–253
  26. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing Ang-1. Science. 1998;282:468–471
  27. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. J. Biol. Chem. 1998;273:18514–18521
  28. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascularspecific growth factors and blood vessel formation. Nature. 2000;407:242–248
  29. Ding H, Roncari L, Wu X, Lau N, Shannon P, Nagy A, et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro Oncol. 2001;3:1–10
  30. Stratmann A, Risau W, Plate KH. Cell typespecific expression of Ang-1 and Ang-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 1998;53:1459–1466
  31. Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS, Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA array. Mol. Med. 2000;6:750–765
  32. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61:445–451
  33. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi K, et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin. Cancer Res. 1999;5:2506–2510
  34. Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO, et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp. Cell Res. 2002;279:299–309
  35. Shim WS, Teh M, Mack PO, Ge R. Inhibition of Ang-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int. J. Cancer. 2001;94:6–15

PII: S0304-3835(05)01038-4

doi: 10.1016/j.canlet.2005.11.039

Cancer Letters
Volume 243, Issue 2 , Pages 246-254 , 18 November 2006

Article Tools

* Image Usage & Resolution